Clinical Trial: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum
Brief Summary: The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
Detailed Summary:
Sponsor: XOMA (US) LLC
Current Primary Outcome:
- Evaluation of treatment-emergent adverse events; [ Time Frame: Up to 2 years ]
- Changes from baseline vital signs, physical examination results, and laboratory test results [ Time Frame: Up to 2 years ]
- Changes from baseline concomitant medications use [ Time Frame: Up to 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: XOMA (US) LLC
Dates:
Date Received: December 8, 2014
Date Started: November 2014
Date Completion:
Last Updated: April 25, 2016
Last Verified: April 2016